[ET Net News Agency, 29 July 2020] Sino Biopharmaceutical Limited (01177) said
"Idarubicin Hydrochloride for Injection" (brand name: Anbijian) (including two
specifications of 5mg and 10mg), a drug for the treatment of Acute Myeloid Leukemia (AML)
developed by the group, has obtained approval for drug registration granted by the
National Medical Products Administration of the People's Republic of China and is deemed
to have passed the Consistency of Quality and Efficacy Evaluation for Generic Drugs.
Idarubicin is a fundamental treatment drug for AML unanimously recommended by domestic
and foreign guidelines. Anbijian developed by the group is the first product of its kind
in the PRC that has passed the consistency evaluation, with advanced formulation
technique, excellent product quality, and good efficacy and safety.
AML is a malignant tumour with high aggression and rapid progression. If left untreated,
the patient will suffer from infection or death from haemorrhage within a few months after
diagnosis. (RC)
|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01177 SINO BIOPHARM
Nominal 
3.300 +0.020 (+0.610%) Others
29/07/2020 12:14
Sino Biopharm (01177) gets drug registration approval
| Remark: | Real time quote last updated: 19/09/2024 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service |